Xinxin Bu

Xinxin Bu

Auto-generated profile, based on publicly available information

Xinxin Bu

Department of Pharmaceutics School of Pharmacy Nanjing Medical University Nanjing China

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2008 in Cancer Biology & Therapy
Verified
Journal Article
Open access
XGXianling Guo
Xianling Guo
WWWeifen Wang
Weifen Wang
FZFeiguo Zhou
Feiguo Zhou
ZLZhenghua Lu
Zhenghua Lu
RFRuifang Fang
Ruifang Fang
LWLixin Wei
Lixin Wei
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. However, there is no effective treatment for HCC. It has been shown that sustained activation of telomerase is essen...

11 November 2021 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
XBXinxin Bu
Xinxin Bu
JLJiuxiang Liu
Jiuxiang Liu
RDRong Ding
Rong Ding
ZLZhi Li
Zhi Li
Background. Osteosarcoma is the most prevalent bone cancer that affects young adults and adolescents. It is the most frequent malignancy of the bone. In spite of the fact that complete surgical resection and chemotherapy have increased the overall survival of osteosarcoma patients considerably, the prognosis remains dismal in patients with recurring and/or metastasized osteosarcoma. Thus, finding predictive biomarkers representing osteosarcoma's biological variability may result in more effective treatment for osteosarcoma patients. Methods. In this research, RNA data and clinical information were obtained from TARGET database. The risk score was calculated using a technique that incorporated both univariate and multivariate Cox regression. A variety of statistical methods were employed to assess the risk score's accuracy. These included ROC curves, nomograms, and Kaplan-Meier curves. Following that, bioinformatics studies were carried out in order to investigate the possible biological processes that influence the prognosis of osteosarcoma patients. GSEA was used to investigate the variations in pathway enrichment among the different groups of genes. To examine the disparities in the immune microenvironment, the analytical methods CIBERSORT and ssGSEA were employed. Results. We discovered three differentially expressed lncRNAs (RPARP-AS1, AC009159.3, and AC124312.3) that are linked to osteosarcoma prognosis. Kaplan-Meier analysis showed the presence of a signature of high-risk lncRNAs linked with a poor prognosis for osteosarcoma. Furthermore, the AUC of the lncRNAs signature was 0.773, indicating that they are useful in predicting osteosarcoma prognosis in certain cases. In predicting osteosarcoma prognosis, our risk assessment approach outperformed conventional clinicopathological characteristics. In the high-risk group of people, GSEA showed the presence of tumor-related pathways as well as immune-related pathways. Furthermore, TARGET revealed that immune-related functions such as checkpoint, T-cell coinhibition, and costimulation were significantly different between the high-risk and low-risk groups. LAIR1, LAG3, CD44, and CD22, as well as other immune checkpoints, were shown to be expressed differentially across the two risk groups. Conclusion. This study established that pyroptosis-derived lncRNAs had a significant predictive value for osteosarcoma patients' survival, indicating that they may be a viable target for future therapy.

15 February 2021 in BMC Veterinary Research
Verified
Journal Article
Open access
PDF file
XLXiuli Li
Xiuli Li
MGMin Gu
Min Gu
XWXiaoquan Wang
Xiaoquan Wang
RGRuyi Gao
Ruyi Gao
XBXinxin Bu
Xinxin Bu
XLXiufan Liu
Xiufan Liu
Background: Genotype S H9N2 viruses have become predominant in poultry in China since 2010. These viruses frequently donate their whole internal gene segments to other emerging influenza A subtypes such as the novel H7N9, H5N6, and H10N8 viruses. We recently reported that the PB2 and M genes of the genotype S H9N2 virus, which are derived from the G1-like virus, enhance the fitness of H5Nx and H7N9 avian influenza viruses in chickens and mice. However, whether the G1-like PB2 and M genes are preferentially incorporated into progeny virions during virus reassortment remains unclear; whether the G1-like PB2 and M genes from different subtypes are differentially incorporated into new virion progeny remains unknown. Results: We conducted a reassortment experiment with the use of a H7N9 virus as the backbone and found that G1-like M/PB2 genes were preferentially incorporated in progeny virions over F/98-like M/PB2 genes. Importantly, the preference varied among G1-like M/PB2 genes of different subtypes. When competing with F/98-like M/PB2 genes during reassortment, both the M and PB2 genes from the H7N9 virus GD15 showed an advantage, whereas only the PB2 gene from the H9N2 virus CZ73 and the M gene from the H9N2 virus AH320 displayed the advantage. Conclusion: Our findings highlight the preferential and variable advantages of H9N2-derived G1-like M and PB2 genes in incorporating them into H7N9 progeny virions over SH14-derived F/98-like M/PB2 genes.

28 September 2026 in Advanced Functional Materials
Verified
Journal Article
Open access
PDF file
XBXinxin Bu
Xinxin Bu
JWJie Wu
Jie Wu
JZJintong Zhou
Jintong Zhou
HWHaisi Wu
Haisi Wu
MSMengna Sun
Mengna Sun
HXHuae Xu
Huae Xu
Glucocorticoids, while central to asthma management, face clinical challenges due to systemic toxicity and acquired resistance, underscoring an urgent demand for novel targeted therapies. Here, a bioinspired hydrogel derived from decellularized lung extracellular matrix (dECM) is engineered for the localized and synchronized co‐delivery of methylprednisolone (MP) and resveratrol (RSV). The resulting RML@dECM platform demonstrates excellent biocompatibility and provides sustained release of both agents within the bronchial microenvironment. Therapeutically, the system effectively alleviates asthma pathology via dual immunomodulatory and anti‐remodeling actions. Mechanistically, RML@dECM restores pulmonary immune homeostasis by rebalancing Th1/Th2 responses and repolarizing macrophages from a pro‐fibrotic M2 toward a protective M1 phenotype, while concurrently inhibiting mucus hypersecretion through modulation of the JAK/STAT signaling pathway. In vivo, RML@dECM surpasses conventional corticosteroid monotherapy, markedly reducing airway hyperresponsiveness, mucus overproduction, and histological damage. Importantly, by confining drug action to the lungs, the platform significantly minimizes systemic exposure and off‐target adverse effects. This work presents a synergistic, locally delivered dual‐drug hydrogel that addresses core limitations in asthma treatment, offering a promising translational strategy for achieving sustained airway immunomodulation with enhanced safety.